How should I manage immunization for a 32‑year‑old adult who is immune to measles (titer 29.40) but non‑immune to mumps (IgG <9.0) and rubella (IgG <0.9)?

Management of Selective MMR Non-Immunity in a 32-Year-Old Adult

This patient should receive one dose of MMR vaccine to protect against mumps and rubella, despite documented measles immunity. 1

Rationale for MMR Vaccination

The 2020 ACIP guidelines clearly state that adults with no evidence of immunity to measles, mumps, or rubella require MMR vaccination. 1 While this patient demonstrates measles immunity (titer 29.40), the non-protective titers for mumps (<9.0) and rubella (<0.9) constitute lack of evidence of immunity to two of the three vaccine components.

Key Principles:

• MMR vaccine is administered as a combination product—you cannot selectively vaccinate against individual components in routine practice. 1

• One dose of MMR is recommended for adults ≥18 years who lack evidence of immunity, with two doses reserved for high-risk groups (healthcare workers, students in post-secondary institutions, international travelers, household contacts of immunocompromised persons). 1

• Pre-existing immunity to one component is not a contraindication to receiving MMR vaccine; the measles component will simply provide a booster effect without causing harm. 1, 2

Evidence of Immunity Criteria

The patient's serologic results should be interpreted as follows:

• Measles: Titer of 29.40 constitutes laboratory evidence of immunity (acceptable). 1
• Mumps: IgG <9.0 indicates lack of immunity (requires vaccination). 1
• Rubella: IgG <0.9 indicates lack of immunity (requires vaccination). 1

Important caveat: Physician-diagnosed disease without laboratory confirmation is no longer accepted as evidence of immunity for measles or mumps as of the 2013 ACIP update. 2 Only laboratory-confirmed disease or documented vaccination constitutes acceptable evidence.

Vaccination Schedule

Administer one dose of MMR vaccine now. 1

Consider a Second Dose If:

• The patient is a healthcare worker (two doses required regardless of serologic results). 1, 2
• The patient is a student in a post-secondary educational institution. 1
• The patient is an international traveler. 1
• The patient is a household or close personal contact of an immunocompromised person. 1

If any of these high-risk categories apply and the patient has never received MMR or received only one dose previously, administer a two-dose series at least 4 weeks apart. 1

Safety Considerations

There is no increased risk from revaccinating someone already immune to measles. 2, 3 Studies demonstrate that:

• Boosting pre-existing measles antibodies does not cause adverse events beyond standard vaccine reactions. 3
• The measles component will provide an anamnestic response without harm. 3
• MMR vaccine has a well-established safety profile in adults. 4, 5

Common Pitfalls to Avoid

Do not order IgM testing for immunity assessment. 6 IgM testing is appropriate only when acute measles, mumps, or rubella infection is suspected—not for determining immune status. 6 Recent data show that 84.6% of measles IgM tests, 67.2% of mumps IgM tests, and 89.8% of rubella IgM tests performed in the U.S. were inappropriate. 6

Do not delay vaccination to obtain additional serologic testing. 1 The patient's current titers clearly demonstrate non-immunity to mumps and rubella, and further testing would only postpone necessary protection.

Do not attempt to obtain monovalent mumps or rubella vaccines for routine use—these are not readily available in the United States, and MMR is the standard of care. 1, 2

Post-Vaccination Monitoring

Routine post-vaccination serologic testing is not recommended unless the patient receives immune globulin within 14 days of MMR vaccination, in which case titers should be checked ≥3 months later to confirm seroconversion. 7

Expected antibody response: After a single MMR dose in previously seronegative adults, approximately 93-95% develop protective measles antibodies, 73-90% develop protective mumps antibodies, and 97-99% develop protective rubella antibodies. 3, 8

Special Populations

If this patient is pregnant: MMR vaccine is contraindicated. 1, 9 Counsel to avoid pregnancy for 28 days after vaccination if administered. 2

If this patient is immunocompromised: MMR vaccine is contraindicated in persons with severe immunosuppression. 1, 9 However, persons with HIV infection without severe immunosuppression (CD4 ≥200 cells/μL for ≥6 months) may receive MMR. 2